Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1083 combination COVID-19 and influenza vaccine in adults ≥50 years
NCT06694389Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, single-blind trial of mCOMBRIAX in coronavirus disease 2019 (COVID-19) and influenza (2 arms), sponsored by Moderna Inc. Primary endpoints: Geometric Mean Level of Antibodies for Influenza by Hemagglutination Inhibition Assay at Day 29, Geometric Mean Level of Antibodies for SARS-CoV-2 by Pseudovirus Neutralization Assay at Day 29 and 6 more. Started Nov 2024; status: completed.
02
Drugs
mCOMBRIAX
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06694389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06694389.